|
Soft Tissue Regeneration, Inc. |
|
|
142 Temple Street, Suite 206 New Haven, CT 06510 USA phone:973-879-6367 fax:
|
|
| Symbol |
Private |
| Founded |
2008 |
| Employees |
1 |
|
|
| www.SoftTissueRegeneration.com
|
|
| Research Sector |
Medical Devices & Tech |
|
 |
| Summary Description |
| Soft tissue regeneration for sports medicine |
 |
| Management |
| Joseph W. Reilly, President and CEO;
Cato T. Laurencin, MD, PhD, Scientific Founder; |
| |
|
|
| |
|
| Keywords |
| sports medicine, ACL, Regenerative, |
|
|
|
| Description |
|
Soft Tissue Regeneration Inc. (“STR”) is a medical device company that defines new technologies for the soft tissue regeneration segment of the sports medicine market. The Company has developed and tested the L-C Ligament®, a breakthrough biodegradable scaffold that in vivo studies have shown to regenerate the anterior cruciate ligament (ACL). Typical ACL repair consists of using autograft material, which entails unpredictable resorption characteristics and may cause damage to surrounding donor tissue, or allograft material, which is taken from cadavers and can transmit disease or infection. The L-C Ligament® is a breakthrough in facilitating the regeneration of native, natural ACL that is capable of carrying normal load after resorption of the scaffold. STR has obtained exclusive worldwide rights to a patent for the L-C Ligament®. This earlier-stage medical device company has also developed the STR GRAFT, a biodegradable scaffold to augment rotator cuff reconstruction, which has proved successful in several large animal studies and is currently undergoing 501(k) approval in the US. |
 |
| Products / Services |
L-C Ligament a biodegradable scaffold to regenerate the ACL.
STR GRAFT a rotator cuff augmentation device.
|
 |
 |
| Funding |
| Raised Series A of $4 million
Seeking a Series B of $7 million with $2 million of convertible notes already raised from current investors. |
 |
|
|
|
|
|
|